<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-91507" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dronabinol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Donnell</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Hofstra Northwell School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meissner</surname>
            <given-names>Hannah</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian O'Donnell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hannah Meissner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-91507.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dronabinol is synthetic tetrahydrocannabinol ('THC'), which obtained FDA approval in 1985 for the treatment of HIV/AIDs-induced anorexia and chemotherapy-induced nausea and vomiting in patients who have failed to respond to conventional antiemetics. Dronabinol has also been used off-label for the treatment of OSA. This activity will provide an overview of the pharmacology of dronabinol, its indications and usage, adverse effects, contraindications, and other pertinent information.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for dronabinol.</p></list-item><list-item><p>Describe the mechanism of action for dronabinol.</p></list-item><list-item><p>Review the potential toxicity of dronabinol.</p></list-item><list-item><p>Identify potential drug interactions with dronabinol.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91507&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91507">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-91507.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Dronabinol is a synthetic form of tetrahydrocannabinol ('THC'), which obtained FDA approval in 1985 for the treatment of HIV/AIDs-induced anorexia and chemotherapy-induced nausea and vomiting ('CINV') in patients who do not successfully respond to conventional antiemetics. Dronabinol also has off-label use to treat obstructive sleep apnea&#x000a0;with mixed and unclear efficacy (only Phase II trials). Therefore, the American Academy of Sleep Medicine does not support its use until reliable data is available (such as Phase III trials).<xref ref-type="bibr" rid="article-91507.r1">[1]</xref>&#x000a0;Recent studies also utilized dronabinol in chronic pain patients, which showed efficacy compared to placebo, but further research is necessary.<xref ref-type="bibr" rid="article-91507.r2">[2]</xref>&#x000a0;Additionally, current fields exploring the use of dronabinol include substance abuse and withdrawal.<xref ref-type="bibr" rid="article-91507.r3">[3]</xref>&#x000a0;</p>
        <p>As such, the indications for this cannabinoid in adults are HIV/AIDs-induced anorexia and chemotherapy-induced nausea and vomiting in patients who&#x000a0;do not successfully&#x000a0;respond to conventional antiemetics.<xref ref-type="bibr" rid="article-91507.r4">[4]</xref><xref ref-type="bibr" rid="article-91507.r5">[5]</xref></p>
      </sec>
      <sec id="article-91507.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Dronabinol is an orally active cannabinoid (a synthetic form of the active delta-9-tetrahydrocannabinol). The majority of effects of cannabinoids and endocannabinoids (endogenous cannabinoids) appear to be carried out by two inhibitory G-protein coupled-receptors (GPCRs), CB1 (present in high levels in several brain regions, including the prefrontal cortex, hippocampus, amygdala, basal ganglia, and the cerebellum) and CB2 (present in a restricted distribution in the brain stem and periphery including immune cells and neurons).<xref ref-type="bibr" rid="article-91507.r6">[6]</xref><xref ref-type="bibr" rid="article-91507.r7">[7]</xref></p>
        <p>When activated, CB1 generally reduces neuronal excitation. Dronabinol, like THC, is a partial agonist at the CB1 receptor. Cannabinoid signaling carries implications in many pathways, including pain modulation, cognition, appetite stimulation, anti-nausea, among others. The anti-emetic and appetite stimulation effects of the CB1 receptor appear to mediate the therapeutic effects of dronabinol.<xref ref-type="bibr" rid="article-91507.r8">[8]</xref><xref ref-type="bibr" rid="article-91507.r9">[9]</xref></p>
      </sec>
      <sec id="article-91507.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Dronabinol is an orally active cannabinoid (a synthetic form of the active Delta-9-tetrahydrocannabinol) that is available in round, soft gelatin 2.5 mg (white), 5 mg (dark brown), and 10mg (orange) capsules. Dronabinol is insoluble in water. As such, it is formulated in sesame oil (providers must inquire about patient allergies). Dosing for specific therapy is outlined below:</p>
        <p>
<bold>HIV/AIDs-induced Anorexia&#x000a0;</bold>
</p>
        <p>The recommended starting adult dosage is 2.5 mg orally twice a day, one hour before lunch and dinner.&#x000a0;</p>
        <p>Dosing Considerations: Elderly patients may not be able to tolerate 2.5 mg twice daily. One may consider 2.5 mg once a day (later in the day may reduce unwanted CNS symptoms)) and titrate up to reduce unwanted CNS symptoms. The unwanted effects of feeling high, dizziness, confusion, and somnolence usually resolve in 1&#x000a0;to 3 days.&#x000a0;</p>
        <p>Titration and Maximum Dosage: Increase gradually to 2.5 mg 1 hour before lunch and 5 mg 1 hour before dinner. Most patients will receive the desired therapeutic effect with this dosage, but dosing can be increased slowly to a maximum of 10 mg twice daily.<xref ref-type="bibr" rid="article-91507.r10">[10]</xref></p>
        <p>
<bold>Chemotherapy-induced Nausea and Vomiting ('CINV') in Patients Who Have Failed to Respond to Conventional Antiemetics</bold>
</p>
        <p>The recommended starting adult dosage is 5 mg orally, which should be taken 1 hour or up to 3 hours before chemotherapy, followed by 5 mg every 2&#x000a0;to 4 hours (4 to 6 total doses in a day). The initial dose should be on an empty stomach and generally is&#x000a0;taken more than 30 minutes before a meal. The patient does not need to consider the timing of meals or food intake regarding subsequent doses after the first dose.</p>
        <p>Dosing Considerations: Similar to dosing for anorexia, elderly patients may be started on a lower dose of 2.5 mg once daily before chemotherapy to reduce CNS symptoms.</p>
        <p>Titration and Maximum Dosage: The drug can be titrated up in amounts of 2.5 mg. The maximum dose is 15 mg for each dose (4 to 6 total doses in a day).<xref ref-type="bibr" rid="article-91507.r10">[10]</xref></p>
        <p>Careful attention is necessary regarding the potential adverse effects of dronabinol during upward titration. See the 'Adverse Effects' and 'Monitoring' sections for further details.</p>
      </sec>
      <sec id="article-91507.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Hypersensitivity to Dronabinol or Sesame Oil: Clinical staff should monitor patients for signs of hypersensitivity reactions. Reported signs include lip swelling, hive, rash, oral lesions, skin burning, and throat tightness.</p>
        <p>Other Adverse Effects: The most common adverse reactions (&#x02265;3%) include abdominal pain, dizziness, euphoria, nausea, paranoid reaction, somnolence, abnormal thinking, and vomiting. Please also see the 'Toxicity' section below.</p>
        <p>Other concerns include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neuropsychiatric Reactions: Dronabinol can precipitate psychiatric and cognitive changes (may need to be avoided in those with psychiatric history). It may also result in mental or physical impairment. Patients should not operate heavy machinery or motor vehicles until one is certain that the drug does not impair their ability to operate.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hemodynamics: Dronabinol can cause hemodynamic instability in patients with existing cardiac disorders. As such, they may experience decreased or increased blood pressure, syncope, or rapid heart rate. Monitor for these changes after beginning treatment and changing doses. Avoid drugs that also affect hemodynamics.</p>
          </list-item>
          <list-item>
            <p>Seizures: Dronabinol can cause seizures or similar events in patients with a prior medical history of seizures. These patients also require&#x000a0;close monitoring, and therapy should stop if a seizure occurs.</p>
          </list-item>
          <list-item>
            <p>Substance abuse: As with any controlled substance or drug with abuse potential, patients should be monitored and assessed for drug misuse risk&#x000a0;(especially in those with substance abuse history).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Paradoxical Nausea and Vomiting: Consider stopping or reducing the treatment dose with dronabinol if the patient experiences a paradoxical increase in nausea and vomiting.<xref ref-type="bibr" rid="article-91507.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-91507.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Dronabinol formulations contain sesame oil. As such, this drug is contraindicated in patients who have a history of hypersensitivity reaction to sesame oil or THC derivatives. Careful attention is necessary for signs of hypersensitivity reactions (see Monitoring below).<xref ref-type="bibr" rid="article-91507.r4">[4]</xref></p>
      </sec>
      <sec id="article-91507.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Metabolism:&#x000a0;Liver via extensive first-pass, cytochrome&#x000a0;P450 2C9, and cytochrome P450 3A4.</p>
        <p>The onset of Action: Generally 0.5 to 1 hour</p>
        <p>Half-life: 4 hours.</p>
        <p>Bioavailability:10 to 20%</p>
        <p>Therapeutic Index (TI): TI is wide, and dosing is limited by adverse effects as a lethal dose of IV dronabinol is estimated at 30 mg/kg or greater. As such, max doses reflect increased rates of adverse effects. See the 'Administration' section for max doses.</p>
        <p>Hypersensitivity to Dronabinol or Sesame Oil: Patients should be monitored for signs of hypersensitivity reactions. Reported signs include lip swelling, hive, rash, oral lesions, skin burning, and throat tightness.</p>
        <p>Other Adverse Effects: The most common adverse reactions (which generally occur in greater than 3% but less than 10% of patients) include pain in the abdomen, nausea or vomiting, feelings of joy, feelings of paranoia, and abnormal thinking. Please also see the 'Toxicity' section below.</p>
        <p>Important Drug Interaction: Drugs that inhibit or induce cytochrome&#x000a0;P450 2C9&#x000a0;and cytochrome P450 3A4 can affect the plasma concentration of dronabinol. Drugs that are typically highly bound by proteins in plasma can be displaced by dronabinol as it is a highly protein-bound drug (with a higher affinity for carrier proteins than most others), increasing patient exposure. Drugs with narrow therapeutic windows, such as warfarin, require close monitoring when co-administered with dronabinol.<xref ref-type="bibr" rid="article-91507.r4">[4]</xref></p>
      </sec>
      <sec id="article-91507.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Toxicity</bold>
</p>
        <p>The estimated lethal dose of IV dronabinol is 30 mg/kg (note this is for illustrative purposes as dronabinol dosing is oral). As such, the CNS toxicity (adverse CNS effects) of dronabinol is more applicable as a measure for monitoring dose-limiting toxicity. Signs and symptoms of toxicity include:</p>
        <p><italic toggle="yes">Mild Intoxication:</italic>&#x000a0;sleepiness, feelings of joy, heightened sensory vigilance, time perception difficulties, conjunctival injection, dry oral cavity,&#x000a0;and&#x000a0;elevated heart rate.</p>
        <p><italic toggle="yes">Moderate Intoxication:</italic> Memory difficulty, feelings of detachment, mood changes, retention of urine, and decreased bowel motility.</p>
        <p><italic toggle="yes">Severe:</italic> Decreased coordination of motor function, lethargy, slurring of speech, and orthostatic hypotension.</p>
        <p>Panic attacks in those with apprehension and seizures in those with a history of seizures can&#x000a0;also occur.<xref ref-type="bibr" rid="article-91507.r11">[11]</xref></p>
        <p>
<bold>Management of Serious Ingestion</bold>
</p>
        <p>There is no specific antidote for the treatment of dronabinol toxicity. If there is a history of recent excessive ingestion, the patient should have gut decontamination with activated charcoal (at a dosage of 30 to 100g for adults, 1 to 2 g/kg in infants). Delivery&#x000a0;through a&#x000a0;nasogastric tube may be necessary for an unconscious patient with a secure airway. Patients with intense psychiatric complications (such as depressive episodes, hallucinations, or psychosis) may need to be isolated in a quiet and peaceful area and frequently reassured by the provider or staff. Benzodiazepines, such as diazepam (5 to 10 mg PO), can be utilized for extreme agitation. Hypotension is manageable with Trendelenburg positioning and isotonic IV hydration.<xref ref-type="bibr" rid="article-91507.r11">[11]</xref></p>
      </sec>
      <sec id="article-91507.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing anorexia associated with weight loss in patients with AIDs/HIV and nausea and vomiting that can accompany chemotherapy in patients who have not responded to traditional conventional antiemetics requires an interprofessional team of healthcare professionals that may include clinicians&#x000a0;of various types (MDs, DOs, NPs, and PAs), palliative care specialists, oncology specialists, pharmacists, nursing staff, and other clinicians from other specialties. The interprofessional model will involve open communication and information sharing, with each interprofessional team member empowered to contribute to the patient case from their own expertise to drive optimal patient outcomes. [Level 5]</p>
        <p>
<bold>Anorexia Associated with Weight Loss in Patients with AIDs/HIV</bold>
</p>
        <p>Level 1: Treatment of AIDs-related anorexia and weight loss was proven effective in a randomized, double-blind, placebo-controlled study with 139 patients. A statistically significant difference between dronabinol and placebo was observable in appetite. Additional measured trends included improved body weight and mood and decreases in nausea. Recent metanalyses have also shown dronabinol to be efficacious.<xref ref-type="bibr" rid="article-91507.r12">[12]</xref></p>
        <p>
<bold>Nausea and Vomiting Associated with Chemotherapy in Patients Who Have Not Responded to Traditional Conventional Antiemetic</bold>
</p>
        <p>Level 1: Treatment of chemotherapy-induced nausea and vomiting ('CINV') with dronabinol has been extensively studied as monotherapy and combined with other more traditional antiemetics such as ondansetron. Recent metanalyses have also shown dronabinol to be efficacious.<xref ref-type="bibr" rid="article-91507.r13">[13]</xref><xref ref-type="bibr" rid="article-91507.r14">[14]</xref></p>
      </sec>
      <sec id="article-91507.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91507&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91507">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/91507/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=91507">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-91507.s11">
        <title>References</title>
        <ref id="article-91507.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carley</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Malkani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Attarian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vern</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.</article-title>
            <source>Sleep</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>41</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29121334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schimrigk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marziniak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kugler</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abramov-Sommariva</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients.</article-title>
            <source>Eur Neurol</source>
            <year>2017</year>
            <volume>78</volume>
            <issue>5-6</issue>
            <fpage>320</fpage>
            <page-range>320-329</page-range>
            <pub-id pub-id-type="pmid">29073592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pavlicova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Bisaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dakwar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2016</year>
            <month>Feb</month>
            <day>01</day>
            <volume>159</volume>
            <fpage>53</fpage>
            <page-range>53-60</page-range>
            <pub-id pub-id-type="pmid">26711160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badowski</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Yanful</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>643</fpage>
            <page-range>643-651</page-range>
            <pub-id pub-id-type="pmid">29670357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Glode</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.</article-title>
            <source>Cancer Manag Res</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>49</fpage>
            <page-range>49-55</page-range>
            <pub-id pub-id-type="pmid">27274310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morales</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jagerovic</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Novel approaches and current challenges with targeting the endocannabinoid system.</article-title>
            <source>Expert Opin Drug Discov</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>917</fpage>
            <page-range>917-930</page-range>
            <pub-id pub-id-type="pmid">32336154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reuter</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>807</fpage>
            <page-range>807-812</page-range>
            <pub-id pub-id-type="pmid">26883879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badowski</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>441</fpage>
            <page-range>441-449</page-range>
            <pub-id pub-id-type="pmid">28780725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natale</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.</article-title>
            <source>Hosp Pract (1995)</source>
            <year>2015</year>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>226</fpage>
            <page-range>226-34</page-range>
            <pub-id pub-id-type="pmid">26308912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bar-Sela</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zalman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Semenysty</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ballan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.</article-title>
            <source>Integr Cancer Ther</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>18</volume>
            <fpage>1534735419881498</fpage>
            <pub-id pub-id-type="pmid">31595793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badowski</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS.</article-title>
            <source>HIV AIDS (Auckl)</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">26929669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;user</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Welsch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radbruch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fitzcharles</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A&#x000a0;systematic review with meta-analysis of randomised controlled trials.</article-title>
            <source>Schmerz</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>424</fpage>
            <page-range>424-436</page-range>
            <pub-id pub-id-type="pmid">31073761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;cke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuhls</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Radbruch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>H&#x000e4;user</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis of cannabinoids in palliative medicine.</article-title>
            <source>J Cachexia Sarcopenia Muscle</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-234</page-range>
            <pub-id pub-id-type="pmid">29400010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91507.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eccleston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Finnerup</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Gilron</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haroutounian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krane</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>ASC</given-names>
              </name>
              <name>
                <surname>Rowbotham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials.</article-title>
            <source>Pain Rep</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>e741</fpage>
            <pub-id pub-id-type="pmid">31583356</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
